P2.03a-003 Belinostat in Combination with Carboplatin and Paclitaxel in Patients with Chemotherapy-Naive Metastatic Lung Cancer (NSCLC)

Abstract

to evaluate patterns of chemotherapy use. Median, 1-year and 2-year OS were calculated for patients that received chemotherapy using Kaplan Meier method. Results: Among the 86,200 patients that met the eligibility criteria, 40,147 (46.6%) patients received chemotherapy, which included single agent (n¼3,912; 9.7%) multiagent (n¼32,737; 81.5%) and number of agents unknown (n¼3,498; 8.7%). A total of 46,053 (53.43%) patients did not receive chemotherapy due to chemotherapy not recommended (n¼5,397; 11.7%), patient refusal (n¼6,119; 13.3%) and other/unknown reasons (n¼34,537; 75%). Patients receiving multi-agent chemotherapy were younger than those receiving single agent chemotherapy (65.6 vs 71.5 years). Chemotherapy use declined with increase in comorbidity score (50.4% for score of 0, 44% for score of 1 and 36.2% for score of 2). The median, 1-year and 2-year OS for patients receiving chemotherapy were 7.5 months, 30.6% and 11.8% respectively (Table). Conclusion: Most patients with metastatic SCC do not receive chemotherapy. The OS for patients with metastatic SCC remains poor, especially in patients over the age of 70, in men and those with multiple comorbidities.

Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies

“… 41 Belinostat was combined with carboplatin and paclitaxel for good results in metastatic lung cancer. 42 The human acute myeloid leukaemia, multiple myeloma, and lymphoblastic leukaemia, belinostat was synergized with proteasome inhibitor bortezomib, eicosanoid biosynthesis inhibitor dexamethasone. 26,39 Therefore, compound 7f was also evaluated for its synergistic effect with the protease inhibitor bortezomib against the MOPC-315 multiple myeloma cells ( Table 2 ).…”

Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?

“…Median PFS was 5.7 months. The objective response rate was 35%, all responses being partial responses ( Waqar et al, 2016 ). A phase I trial combining panobinostat with standard doses of carboplatin and etoposide was terminated because of prohibitive side effects of severe thrombocytopenia and febrile neutropenia at the lowest dose of panobinostat ( Tarhini et al, 2013 ).…”

Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer

“…In 13 out of 23 patients RR was available. PR was seen in 35%, stable disease (SD) in 17% and only one patient had a progressive disease (PD) [51]. Compared to carboplatin/paclitaxel alone, the combination with an HDACi appears promising [49].…”